Chongqing Leimei Pharmaceutical Co., Ltd. - Feasibility Study on the Acquisition of Prescription Nutritional Supplement Products
Company overview
Chongqing Leimei Pharmaceutical Co., Ltd. (hereinafter referred to as 'Leimei') was established in 1999 and listed on the Shenzhen Stock Exchange in 2006. It is a modern pharmaceutical enterprise specializing in the research, production, and sales of prescription drugs. The company's product portfolio spans multiple therapeutic areas including anti-infective agents, oncology, cardiovascular and cerebrovascular diseases, and nutritional supplements, with a robust product line and strong R&D capabilities. Leimei has established a notable presence in the domestic prescription drug market. In recent years, the company has actively pursued product structure optimization and resource integration, leveraging a dual-drive strategy of independent R&D and external acquisitions to continuously enhance its core competitiveness, aiming to become a comprehensive pharmaceutical group with sustained innovation capability and market leadership in China's pharmaceutical industry.
Research background
With the accelerating trend of population aging and increasing health demands among specific population groups, the market for prescription nutritional supplements has emerged as a key strategic direction for pharmaceutical companies. The targeted prescription nutritional supplement product under consideration by Leimei primarily serves pediatric and female patient populations, including premature infants, post-surgical recovery cases, and individuals with special nutritional needs—groups with significant clinical demand and broad market potential. The product has achieved coverage in major hospitals across the country, is included in the medical insurance Category B list, and has been incorporated into multiple provincial centralized procurement directories, making it one of the rare assets in the current market that offers both immediate revenue potential and long-term growth prospects. Facing challenges related to market access mechanisms, academic promotion resource allocation, and competitive product landscapes, Leimei urgently requires a systematic research effort to support the scientific and forward-looking nature of this acquisition decision.
Research scope
In June 2025, CEIDEA Research was commissioned by Leimei Pharmaceutical to conduct a specialized feasibility study on the proposed acquisition of prescription nutritional supplement products. The study adopted a multi-method comprehensive research approach, including policy analysis, interviews with key experts, clinical and market performance assessments of leading competitive products, and in-depth interviews with distributors. The research comprehensively evaluates market trends in the nutritional supplement sector, market potential for target indications, end-user behavior, hospital access barriers and the impact of centralized procurement, brand reputation, and physician engagement. The focus is particularly on the specific healthcare needs of children and women, especially in early-term neonatal and post-surgical recovery scenarios, and on the actual clinical value of the product in these settings. The study also systematically identifies and analyzes the product's market positioning, sales logic, and potential risk factors, providing empirical support for post-acquisition integration and sales continuity.
Expected outcomes
This study is expected to produce a comprehensive and systematic feasibility report, providing data support and strategic recommendations for Leimei's acquisition strategy in the prescription nutritional supplement segment. The research outcomes will help the company identify the true value of the target asset within the current policy environment and market dynamics, clarify key market entry priorities and resource allocation strategies following acquisition, and strengthen coverage of key hospital channels and expert networks. Additionally, the study will provide direction for building an academic promotion system, promoting the company's specialized development in the niche market of special population nutrition, and establishing a growth mechanism driven by product leadership and brand influence, thereby enhancing long-term strategic competitiveness in this domain.
Scan to add our research consultant